🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

265 results for “LG” Clear

  1. SECUKINUMAB

    Novartis Pharmaceuticals

    Polymyalgia Rheumatica

    phase 3 small molecule active

    1 trial

  2. Saline, 0.9% sodium chloride solution IV infusion marketed authorized will be used as the placebo and will be supplied by the site. the SmPC previously authorized are Country specific. for Belgium, Spain and Sweden per local requirements under CTDs no SmPCs were submitted., Delandistrogene moxeparvovec-rokl

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

  3. Sarilumab SAR153191 (REGN88)

    Regeneron UK Limited

    Polymyalgia Rheumatica

    phase 3 small molecule terminated

    1 trial

  4. Sodium Oxybate

    Jazz Pharmaceuticals Ireland Limited

    Fibromyalgia

    phase 3 small molecule completed

    1 trial

  5. TAK-583

    Takeda

    Neuralgia, Postherpetic

    phase 3 small molecule completed

    1 trial

  6. TAK-625

    Takeda

    Alagille Syndrome (ALGS)

    phase 3 small molecule completed

    1 trial

  7. TNX-102 SL

    Tonix Pharmaceuticals Holding

    Fibromyalgia

    phase 3 small molecule completed

    2 trials

  8. TNX-102 SL

    Tonix Pharmaceuticals Holding

    Primary Fibromyalgia

    phase 3 small molecule completed

    1 trial

  9. TNX-102 SL 2.8mg

    Tonix Pharmaceuticals Holding

    Primary Fibromyalgia

    phase 3 small molecule completed

    1 trial

  10. TNX-102 SL Tablet 2.8 mg

    Tonix Pharmaceuticals Holding

    Primary Fibromyalgia

    phase 3 small molecule completed

    1 trial

  11. TNX-102 SL Tablet, 2.8 mg

    Tonix Pharmaceuticals Holding

    Fibromyalgia

    phase 3 small molecule terminated

    1 trial

  12. TNX-102 SL Tablet, 2.8mg

    Tonix Pharmaceuticals Holding

    Fibromyalgia

    phase 3 small molecule completed

    1 trial

  13. TNX-102 SL Tablet, 5.6 mg

    Tonix Pharmaceuticals Holding

    Fibromyalgia

    phase 3 small molecule completed

    1 trial

  14. Tapentadol IR 50 mg

    Janssen Cilag International NV

    Hallux Valgus

    phase 3 small molecule completed

    1 trial

  15. Tbo-filgrastim

    Teva Pharma GmbH

    Healthy Participants

    phase 3 small molecule terminated

    1 trial

  16. Thalidomide

    Celgene Europe Limited

    Multiple Myeloma

    phase 3 small molecule completed

    1 trial

  17. Tigulixostat

    LG Chem

    Gout

    phase 3 small molecule completed

    2 trials

  18. Topotecan HEXAL 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Anastrozol STADA® 1 mg Filmtabletten, Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, VS-6766, LETRO-cell® 2,5 mg Filmtabletten, VS-6063, Letrozol - 1 A Pharma® 2,5 mg Filmtabletten, ZOLSKETIL pegylated liposomal 2 mg/mL concentrate for dispersion for inf

    Vera Therapeutics

    Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

    phase 3 small molecule active

    1 trial

  19. Trifarotene 0.005 % Topical Cream

    Teva Pharma GmbH

    Acne Vulgaris

    phase 3 small molecule completed

    1 trial

  20. VINCRISTINE SULFATE, RITUXIMAB, RITUXIMAB, APIXABAN, Golcadomide, PREDNISONE, DOXORUBICIN HYDROCHLORIDE, CYCLOPHOSPHAMIDE MONOHYDRATE, Golcadomide, Golcadomide 0.2 mg capsule, Golcadomide 0.3 mg capsule, Golcadomide 0.4 mg capsule, Golcadomide, Neulasta 6 mg solution for injection, PREDNISOLONE , VINCRISTINE SULFATE

    Celgene Europe Limited

    High-risk Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  21. Xyrem®

    Jazz Pharmaceuticals Ireland Limited

    Fibromyalgia

    phase 3 small molecule completed

    2 trials

  22. Zeposia 0.23 mg hard capsules Zeposia 0.46 mg hard capsules, Zeposia 0.23 mg hard capsules Zeposia 0.46 mg hard capsules, Zeposia 0.92 mg hard capsules

    Celgene Europe Limited

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  23. Zolgensma 2 × 10^13 vector genomes/mL solution for infusion

    Novartis Pharmaceuticals

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  24. filgrastim

    Solid Biosciences

    Lung Cancer

    phase 3 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources